Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 1.00 |
| ▸ | MAOB | P27338 | 11/20 | 1.00 |
| ▸ | MAOA | P21397 | 5/20 | 1.00 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iadademstat SCHEMBL25665880 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL14880518 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL14880351 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL14882124 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL14880654 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL14880401 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL19428614 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL19409823 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL20260493 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| Iadademstat SCHEMBL19357557 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | claimed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | claimed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | claimed |
| EP-2776394-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-12-26 | — | — | EP | claimed |
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2016-12-22 | — | — | US | claimed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | claimed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | claimed |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2026-03-17 | — | — | US | disclosed |
| EP-3941465-B1 | METHODS OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER USING KDM1A INHIBITORS SUCH AS THE COMPOUND VAFIDEMSTAT | ORYZON GENOMICS SA (ES) | 2025-09-17 | — | — | EP | disclosed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| EP-4512473-A2 | METHODS OF TREATING BEHAVIOR ALTERATIONS | Oryzon Genomics, S.A. (ES) | 2025-02-26 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-10-17 | — | — | US | disclosed |
| US-9469597-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-10-18 | — | — | US | disclosed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 147/4885MAOA 135/4885 |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | KDM1A 1/4885MAOB 186/4885MAOA 175/4885 |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | KDM1A 1/4885MAOB 186/4885MAOA 175/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOB 3928/4885MAOA 4155/4885 |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK3, CDKN1A, CDKL3 | KDM1A 26/4885MAOB 2453/4885MAOA 3373/4885 |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | KDM1B, DOT1L, EZH2 | KDM1A 10/4885MAOB 2291/4885MAOA 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.